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Abstract  
Cancer is a lethal disease and ranks as the world’s second most prevalent cause of death. So far, 
tissue-based biopsy is conducted routinely to detect and monitor the progression of cancer. However, the 
traditional technique is deemed too invasive and cannot be used repeatedly. On the other hand, liquid 
biopsy, also known as blood-sample test, has recently surged and has been proved to be more and more 
promising. Using cell-free DNA (cfDNA) and circulating tumor DNA (ctDNA), liquid biopsy can 
effectively profile the genetic landscape of cancer and can detect the presence of cancer in patients at 
very early stages due to its high sensitivity. Liquid biopsy is not only capable of monitoring the risk or 
potential of tumorigenesis, but also capable of predicting and tracking metastasis and relapse. Therefore, 
liquid biopsy is believed to revolutionize cancer detection, prognosis, and personalized medicine 
treatment. In this review, the concept, history, recent advances of liquid biopsy, and existing commercial 
companies’ most commonly used techniques were summarized; the advantages and disadvantages and 
the broad applications of liquid biopsy in various fields including cancer were discussed.  
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Introduction 
Cancer is a lethal disease; with more than 1.68 million of estimated new cases and more than 595,000 
of estimated deaths in 2016 [1], it is the second leading cause of death in the United States after heart 
disease. Heterogeneous both at the cellular and molecular levels, cancers are a variety of diseases that 
involve accelerated cell growth and can invade other parts of the body, a process known as metastasis 
[2]. Because cancer patients harbor unique mutations in genes, effective cancer detection and 
treatment have to become more personalized and are, therefore, more challenging to accomplish [3], 
[4]. Tissue biopsy, a procedure that involves removing a piece of tissue for further laboratory analysis, 
is the conventional way to determine tumor progression but is criticized as being too invasive [5]. On 
the other hand, liquid biopsy, or blood sample tests conducted to identify tumor cells, is deemed 
non-invasive [6]. Therefore, scientists and researchers now consider liquid biopsy more promising in 
cancer early detection. While tissue biopsy is invasive, has unsatisfactory cancer early detection, and 
has limited evaluation of prognosis, liquid biopsy can detect the mutations of the original tumor, is 
highly sensitive and specific, and can determine tumor prognosis and progression [7].  
The desire to use non-invasive techniques to detect diseases has driven scientists and 
researchers for centuries. In 1869, Australian pathologist John Ashworth discovered the presence of 
circulating tumor cells, or CTCs, in the blood that could be used to study tumor biology [8]. In 1948, 
another type of identification was discovered: circulating tumor DNA, or ctDNA [9]. It was not until 
1977 that ctDNA was demonstrated to be linked to cancer [10]. Following a series of technological 
advancements, a sequencing approach using mutation-specific primers to facilitate the polymerase 
chain reaction, or PCR, was developed in the 1990s [11], [12]. Studies implementing this method 
allowed scientists to discover specific mutations in ctDNA [13]. Besides cancer, other areas of study 
using ctDNA include prenatal diagnostics, like determining fetal aneuploidy, as well as organ 
transplants [14], [13].  
Extensive advancements in technology have allowed for the development of new approaches 
and methods in liquid biopsy. Besides the PCR-based sequencing technique, massively parallel 
sequencing, or MPS, and target and whole genome/exome sequencing have become popular for their 
generalized and comprehensive approach [13]. Improvements in technology have also driven the cost 
of sequencing down. Just a couple years ago, sequencing an entire genome would have taken millions 
of dollars; however, Illumina’s recently proposed sequencing method called NovaSeq aims to charge 
only $100 per genome and may be completed in an hour [15]. The advancements made have also led 
to the accumulation of knowledge about somatic mutations in DNA of diseases, such as cancer. For 
example, the Catalogue of Somatic Mutations in Cancer, or COSMIC, is one of the most 
comprehensive databases depositing the somatic mutations in human cancer [16]. Circulating tumor 
DNA (ctDNA) is produced by dead tumor cells and flows into the bloodstream [17]. Based on the 
knowledge obtained, the ctDNA in cancer patients’ plasma have led to the detection of somatic 
mutations in DNA, and some actionable mutations in cancer genes have been identified using liquid 
biopsy [18]. CAPP-Seq, a recently developed method by Stanford University and acquired by Roche, 
evaluates ctDNA to profile lung cancer and would reduce costs and increase sensitivity [19]. Currently, 
many commercial start-ups have been established focusing on further developing this field. Racing to 
develop liquid biopsies, more than 40 commercial companies are currently working on furthering this 
promising field: to name a few, Guardant Health, Grail, and Foundation Medicine. In addition to 
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mutations, RNA and DNA methylation patterns have also been detected using ctDNA [20]. The 
applications of liquid biopsy are not limited to diseases. With the advent of machine learning, 
scientists aim to combine both sequencing depth and genomic coverage breadth to accurately 
categorize people into normal or disease-associated [21].  
CTCs and ctDNA 
The discovery of circulating tumor cells, or CTCs, in the 1800s brought about a deeper understanding 
of cancer and tumor biomarkers [8]. Clusters of these cells usually enter the bloodstream via 
epithelial-to-mesenchymal transition, or EMT, and are considered to be one of the most likely reasons 
for metastasis, or spreading of the tumor [22]. A study revealed that a lower level of CTCs, less than 5 
per 7.5 mL of blood, correlated to better overall survivability of about 8 months in 177 breast cancer 
patients [23]. Another study concluded that how well a particular drug treatment performed 
corresponded to certain changes in the CTCs’ pathways, such as androgen receptor reactivation and 
amplification in prostate cancer: about 99% of the CTCs disappeared after 3 months of initiation of 
androgen deprivation therapy [24]. Therefore, for many years, scientists and researchers used CTCs 
and the amount of CTCs in a patient’s blood as a tumor biomarker and way to determine the 
effectiveness of treatment methods.  
 Although CTCs have allowed scientists and researchers to understand the cancer better, there 
are still many problems that occur and improvements that can be made, especially involving tumor 
heterogeneity, surface markers, and detection methods. For example, the gene expression patterns 
varied between CTCs from the same patient and between different patients’ CTCs, which indicates 
that the clinical value of CTCs is yet to be determined because of its high variability [25]. In addition, 
because CTCs undergo EMT, they do not express epithelial phenotypes and are harder to detect since 
CTC detection relies on epithelial markers [26], [27]. Because of this, CTC detection needs to be 
improved to include biomarkers that will not be influenced by EMT [28]. Moreover, some CTCs can 
adopt endothelial cell behaviors, which would allow them easier access to the bloodstream [8]. 
Therefore, current methods can only detect a subset of the CTCs. Another challenge in CTC detection 
lies with the techniques used; many methods involve permeating the cells, which reduces their 
viability and prevents further characterization to occur [26].  
 Besides CTCs, circulating tumor DNA, or ctDNA, is also a promising tumor biomarker, one 
that has become the more preferred over CTCs. As tumor cells die or undergo apoptosis, many of 
these cells release ctDNA into the bloodstream; another source of ctDNA is determined to be CTCs 
[18]. Cell-free DNA, or cfDNA, is double-stranded and highly fragmented, most of which are 150 bbp 
in length. Therefore, the detection of cfDNA/ctDNA is easier. Because, unlike CTCs, ctDNA is 
directly exposed in the blood, it does not need to undergo cell isolation, making it more accessible. 
ctDNA is characterized by its single-nucleotide mutations, methylation changes, and cancer-derived 
viral sequences [7]. Currently, several methods have been developed to detect cfDNA, including 
BEAMing, dPCR, next-generation sequencing [29], and so on. Numerous companies have emerged 
with their own technologies and gene panels.  
The wide applications of ctDNA include cancer early detection; identification of 
tumorigenesis, detection of metastasis and cancer relapse; as well as selection of treatment methods 
and drugs. For cancer early detection, one study found that serum from cancer patients were able to 
induce in vitro normal cell tumorigenesis but did not occur when the serum was deprived of DNA [30], 
[31]. Another study discovered that ctDNA levels differed in different stages of diseases like 
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pancreatic, breast, and colorectal cancer [18]. In addition to tumorigenesis, it has been discovered that 
ctDNA is associated with distant metastasis. For example, a significant increase in ctDNA levels was 
correlated to metastasis of colorectal cancer [32], and distant metastasis resulted from the transfer of 
ctDNA from tumor to normal cells through apoptosis [31]. ctDNA analysis can also be applied to 
detection of relapse. Because ctDNA has a relatively short half-life compared to other protein-based 
biomarkers, monitoring a patient’s ctDNA levels more accurately reflects the real-time situation of the 
patient [7], and the varying levels of ctDNA can be used to identify relapsing and non-relapsing 
patients [20]. Since tumors constantly evolve, treatment resistance has become a major issue. Studies 
have shown that through analyzing ctDNA, mutations in markers of therapy resistance can be detected. 
For example, some KRAS gene mutations that are markers of therapy resistance were detected while 
analyzing ctDNA in lung cancer [33], and another study using ctDNA discovered mutations that 
prevented the drug from binding with its targets [29]. Therefore, ctDNA can also be used to help 
clinicians choose the most effective drugs for each patient. The promising potential of ctDNA analysis 
in clinical applications has led to the establishment of many commercial companies and a funding of 
$1 billion for Grail’s liquid biopsy tests among large populations [34].  
Commercial Companies 
Liquid biopsy is a promising direction for cancer early detection and has potential applications in 
therapy and diagnosis. Therefore, many commercial companies have developed their own products for 
liquid biopsy tests for use in research or clinical trials. Three of these nationwide companies that are 
located in Silicon Valley are Grail, Guardant Health, and Natera. Table 1 summarizes the oncology 
product and method for each company.  
 
TABLE 1. Commercial companies developing liquid biopsy tests 
Company (Year) Product (Year) Method References 
Biocartis 
(2009) 
Idylla 
(2014) 
Fully automated, real-time PCR based molecular diagnostics 
system, 30 biomarkers 
[35] 
Chronix 
Biomedical 
(1997) 
Second Opinion 
(2016) 
Next generation sequencing – the technique that has 
successfully mapped the whole human genome 
[36] 
Cynvenio 
(2008) 
ClearID 
(2015) 
Targeting and sequencing of genes known to be somatically 
altered in cancer 
[37] 
Exosome 
Diagnostics (2008) 
ExoDx 
(2016) 
Detection of mutations in certain genes from exosomes 
extracted from urine and blood 
[38] 
Foundation 
Medicine (2010) 
FoundationACT 
(2016) 
Blood-based ctDNA assay identifying base substitutions, 
insertions and deletions, copy number variations, and 
rearrangements/gene fusions, 62 cancer-associated genes 
[39] 
Genomic Health 
(2000) 
Oncotype SEQ 
(2016) 
Next-generation sequencing to identify and assess actionable 
genomic alterations, 17 genes 
[40] 
GRAIL (2016) --- High-intensity sequencing to surface clinically actionable 
insights from vast amounts of tumor genome data 
[41] 
Guardant Health 
(2013) 
Guardant360 
(2014) 
Digital sequencing to identify actionable somatic alterations 
across all solid tumor sites, 73 genes 
[42] 
Inivata 
(2014) 
InVision 
(2016) 
Tagged-amplicon sequencing (TAm-Seq™) method, which 
allows amplification and deep sequencing of genomic regions 
spanning thousands of bases from individual copies of 
fragmented DNA, 34 genes 
[43] 
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MDxHealth 
(2003) 
ConfirmMDx 
(2015) 
Detection of a field effect or halo associated with the presence 
of cancer at the DNA Level 
[44] 
Myriad Genetics 
(1991) 
myRisk 
(2013) 
Representation of the next generation of hereditary cancer risk 
testing, 28 genes 
[45] 
Natera 
(2004) 
Constellation 
(software) (2015) 
Next generation sequencing in oncology and non-invasive 
prenatal testing (NIPT) 
[46] 
NeoGenomics 
Laboratories 
(2002) 
NeoLAB 
(2015) 
Targeted tumor profiles and single gene assays for solid tumors 
and hematologic diseases 
[47] 
OncoCyte 
(2014) 
PanC-Dx 
(2015) 
Comparison of gene expression patterns exhibited by cancer 
tissues that get picked up in blood or urine 
[48] 
Personal Genome 
Diagnostics (2010) 
PlasmaSELECT 
(2016) 
Illumina next-generation sequencing to identify mutations and 
translocations, 64 genes 
[49] 
Resolution 
Bioscience 
(2012) 
ctDX-Lung 
(2015) 
Next-generation sequencing of SNPs, insertion and deletions, 
copy number variations (CNVs) / amplifications, and fusions / 
translocations, 21 genes 
[50] 
 
 Grail is a recently established company invested by Illumina and Gates Foundation. The goal 
of the company is to use high-intensity sequencing to generate datasets that can be applied to cancer 
early detection. The main method through which the approach will develop is through analyzing the 
ctDNA of both cancer patients and normal individuals. Grail focuses on the breadth and depth of its 
technology, emphasizing its unique ability to sequence broadly across the genome and its high 
sensitivity to detect ctDNA signals among background noise. Implementing advanced tools in data 
science, Grail seeks to use machine learning, laboratory tests, and clinical trials to generate large scale 
gene panels that yield clinically actionable insights. Because the company’s goal is to develop a 
comprehensive dataset, it plans on conducting laboratory and clinical tests that involve tens of 
thousands of individuals [41].  
 Guardant Health is one of the earliest commercial companies established in the liquid biopsy 
industry. Its product Guardant360 has already been on the market for more than 2 years and covers 
somatic genomic biomarkers for advanced solid tumors. The 73-gene panel identifies actionable 
somatic alterations using a digital sequencing method, which concentrates on improving sensitivity 
and specificity, on tubes of blood. Specifically, Guardant360 uses digital sequencing to identify, tag, 
and make copies of ctDNA. Since next-generation sequencing methods may introduce errors and false 
positives, the product prefers the digital engine, which reduces errors by one thousand fold and grants 
high level specificity to the gene panel. Guardant360 includes a professional advisory board that 
reviews each case after the test is applied and generates an informative report, displaying graphs 
indicating mutation trends, FDA-approved drugs, and current clinical trials [42].  
 Natera originally began as a commercial company targeting prenatal diagnosis tests but is 
also applying its technology to liquid biopsy for cancer detection. Its approach combines multiplexed 
PCR (mPCR) and next-generation sequencing [29] to detect mutations in cfDNA in early-stage 
cancers. In a recently published scientific paper by Natera, the company focused on determining 
whether both ubiquitous and heterogeneous mutations can be detected using this method in non-small 
cell lung cancer. Currently, Natera is collaborating with UCSF in a trial named I-SPY 2, which was 
launched in 2010 and has enrolled more than 1000 breast cancer patients [51]. More products targeting 
cancer are in development [46].  
 The commercial companies mentioned above have unique techniques, which they constantly 
keep improving upon. They seek to optimize their sequencing methods and increase sensitivity, 
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accuracy, and specificity of their products. In addition, they would refine their gene panels, which 
should make them more cost-effective, and convince insurance companies to cover the costs so that 
more patients can benefit from the liquid biopsy tests.  
Advantages and Disadvantages 
Liquid biopsy is an emerging trend in cancer detection. As an alternative to tissue biopsy, the blood 
test shows great promise in detecting genetic mutations in tumors. Therefore, liquid biopsy can be 
applied in numerous fields, including cancer early detection, disease progression, metastasis, relapse, 
and therapy resistance.  
 One of the greatest advantages of liquid biopsy lies in its ability to detect cancer at early 
stages. By analyzing the mutations in and level of ctDNA through liquid biopsy tests, scientists and 
researchers can identify a tumor at an early stage and apply treatments that will have greater success. 
In one particular study, researchers discovered that ctDNA was found in at least half of the patients 
with localized bladder, colorectal, and breast cancer. Those of which were in Stage I, 47% had 
detectable ctDNA levels and could be curable by surgery alone [18]. Another study by a group from 
Stanford University also demonstrated that 50% of Stage I patients with non-small-cell lung cancer 
had detectable ctDNA levels, while ctDNA was detected in 100% of Stages II-IV patients [19].  
 Compared to traditional tissue biopsy methods, liquid biopsy is more capable of detecting 
metastasis, non-invasive, and allows for sufficient follow-up tests. Contrary to tissue biopsies, liquid 
biopsies can detect DNA derived from distinct metastatic sites, which provides more information 
about the disease since one of the challenges in cancer treatment is its heterogeneity [18]. Because of 
liquid biopsy’s non-invasiveness, tests can be performed repeatedly to follow-up with the patient, 
unlike for tissue biopsies. Since tissue biopsies involve removing only part of the tumor, instances 
may occur where there is not enough tissue left for profiling or there is insufficient quality in the tissue 
remaining [52]. From the patients’ perspective, they may experience less pain and medical 
complications resulting from liquid biopsy than tissue biopsy.  
 Due to its high sensitivity, liquid biopsy has been regarded as a test that can predict cancer 
relapse, monitor real-time tumor progression, and identify therapy-resistant mutations. Since the 
concentration of ctDNA in circulation varies at different stages of cancer, researchers and clinicians 
can use the tumors’ genetic makeup to monitor the real-time progression of the cancer and determine 
what types of therapy the patient is resistant to and what types are most effective [53]. For example, a 
study of 400 patients with several types of cancers demonstrated that liquid biopsy was able to identify 
therapy-resistant mutations that had not been detected in tissue biopsy [52]. In another study, across 
five years, diffuse large B-cell lymphoma patients with detectable ctDNA were more likely to 
experience relapse than those who did not have detectable ctDNA. 17 out of 107 had detectable 
ctDNA after therapy, and 15 out of these 17 experienced relapse. These assays also predicted relapse 
3.5 months before CT scans detected any signs of the disease [54]. This correlates with 
therapy-resistance because relapse would occur when the tumor becomes resistant to the specific type 
of therapy offered.  
 Although liquid biopsy shows much promise in cancer detection, it still needs some 
improvements, one of which is consistency in panel design. The major concern is that many 
companies are currently developing their own gene panels to detect cancer. Because of this, results 
depending upon which gene panels were used are inconsistent and may be misleading. In addition, 
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some of the commercial liquid biopsy gene panels designed include an enormous number of genes, 
which is usually comprised of a couple hundred genes and makes the procedure less cost-efficient.  
 Another limitation lies in liquid biopsy tests’ insurance coverage. Because commercial 
companies are working hard to develop liquid biopsy tests, tissue biopsy is still considered the norm, 
and many insurance policies do not cover the blood test costs. In addition, when conflicting results are 
presented by liquid biopsy and tissue biopsy, insurance policies tend to prefer the diagnoses of tissue 
biopsy and therefore claim that liquid biopsy is “not ready for primetime” [55].  
Conclusion and Future Directions 
Liquid biopsy is regarded as one of the most promising techniques in the cancer detection field in 
recent years. The test’s unprecedented sensitivity level allows clinicians and researchers to detect 
cancer in patients at early stages, which provides an opportunity for early treatment. Because of liquid 
biopsy’s non-invasive nature, follow-up examinations can be done at lower risks and repeatedly. The 
technique can be widely used and can be adjusted to target various states of cancer, including 
metastasis and relapse. In addition to cancer detection, liquid biopsy can also monitor treatment and 
therapy. Its ability to detect therapy-resistant mutations in patients allows clinicians and researchers to 
determine the most effective personalized treatment option for each individual patient.  
 In addition to cancer, liquid biopsy can be extended to many other types of diseases, 
including prenatal testing, organ transplantations, and autoimmune diseases. Non-invasive prenatal 
testing (NIPT) is a field that can effectively use liquid biopsy. The test analyzes blood samples that 
include the mother and child’s cell-free DNA to detect certain types of genetic diseases that the child 
may carry or exhibit. Natera is well-known for conducting NIPT tests, and recently using liquid biopsy, 
their researchers have been able to detect fetal aneuploid abnormalities of chromosomes 13, 18, 21, 
and X, especially triploidy [56]. In addition to prenatal testing, cell-free DNA and liquid biopsy can 
also be applied to organ transplantations. A recent study demonstrated that liquid biopsy can analyze 
donor-derived cell-free DNA to detect the risk of rejection and monitor the health of the transplanted 
tissue [57].  
 With future improvements to the technique, liquid biopsy can be part of an annual routine 
examination. The expected gradual decrease in the cost of the test may provide an opportunity for 
liquid biopsy to become a regular screening practice. Through this, not only cancer patients but also 
normal individuals will have access to liquid biopsy tests. Although clinicians and researchers face 
certain obstacles in developing an optimal screening test, liquid biopsy is an emerging trend and 
promising opportunity in the field. Low-cost next-generation sequencing combined with advanced 
ways to process and analyze data, such as machine learning, may enable them to make breakthroughs 
in cancer detection and other diseases.  
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